RPID Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.920

Open

3.800

VWAP

3.82

Vol

132.26K

Mkt Cap

171.53M

Low

3.660

Amount

504.78K

EV/EBITDA(TTM)

--

Total Shares

44.32M

EV

149.30M

EV/OCF(TTM)

--

P/S(TTM)

5.62

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

Show More

Events Timeline

(ET)

2026-01-13

16:20:00

FY25 Revenue Reaches $33.6M, Exceeding Expectations

2025-11-07 (ET)

2025-11-07

06:14:17

Rapid Micro Biosystems increases FY25 revenue forecast to $33.0M, up from $32M

2025-11-07

06:13:02

Rapid Micro Biosystems announces Q3 earnings per share of 26 cents, exceeding consensus estimate of 25 cents.

2025-09-22 (ET)

2025-09-22

08:13:01

Trinity Capital invests $45 million in growth funding for Rapid Micro Biosystems.

2025-08-12 (ET)

2025-08-12

06:35:32

Rapid Micro Biosystems reports Q2 EPS (27c), consensus (25c)

2025-05-27 (ET)

2025-05-27

09:12:46

Rapid Micro Biosystems appoints Bika to board of directors

2025-05-09 (ET)

2025-05-09

07:06:30

Rapid Micro Biosystems sees FY25 revenue at least $32M

News

NASDAQ.COM

01-14NASDAQ.COM

China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%

seekingalpha

01-14seekingalpha

Rapid Micro Biosystems (RPID) Reports Q4 Revenue of $11.3M, Raises 2025 Guidance to $33M

seekingalpha

01-14seekingalpha

Rapid Micro Biosystems (RPID) Projects 2025 Revenue of $33.6 Million, Up 20%

Yahoo Finance

2025-11-08Yahoo Finance

Highlights from Rapid Micro Biosystems Inc (RPID) Q3 2025 Earnings Call: Record Revenue Achieved

NASDAQ.COM

2025-11-07NASDAQ.COM

RAPID MICRO BIOSYSTEMS, INC. Reports Q3 Loss Below Expectations

Newsfilter

2025-10-30Newsfilter

Rapid Micro Biosystems to Attend the Stifel 2025 Healthcare Conference

3 Analyst Rating

Wall Street analysts forecast RPID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPID is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Lake Street

NULL -> Buy

initiated

$8

AI Analysis

2025-07-28

Reason

Lake Street

Price Target

$8

AI Analysis

2025-07-28

initiated

NULL -> Buy

Reason

Lake Street initiated coverage of Rapid Micro Biosystems with a Buy rating and $8 price target. Rapid is \"emerging as the category leader\" in microbial quality control automation with its Growth Direct platform, says the analyst, who believes the market has yet to fully appreciate the already existing scale and growing adoption of Growth Direct. The firm sees further upside as recurring revenue continues to scale given \"the stickiness of the platform,\" the analyst added.

Keybanc

Paul Knight

Buy

Initiates

$8

2025-02-12

Reason

Keybanc

Paul Knight

Price Target

$8

2025-02-12

Initiates

Buy

Reason

KeyBanc initiated coverage of Rapid Micro Biosystems with an Overweight rating and $8 price target. The analyst believes Rapid Micro's Microbial Growth Direct System is "changing the paradigm" in biological manufacturing quality control. The system is more accurate and provides digital results in three to five days versus manual methods in 5-14 days, the analyst tells investors in a research note. KeyBanc says Rapid Micro is gaining wide adoption in the biopharmaceutical industry that will increase sales visibility and improve margins.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPID

Unlock Now

Valuation Metrics

The current forward P/E ratio for Rapid Micro Biosystems Inc (RPID.O) is -3.69, compared to its 5-year average forward P/E of -3.33. For a more detailed relative valuation and DCF analysis to assess Rapid Micro Biosystems Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.33

Current PE

-3.69

Overvalued PE

0.55

Undervalued PE

-7.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.02

Current EV/EBITDA

-2.68

Overvalued EV/EBITDA

3.73

Undervalued EV/EBITDA

-7.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

6.31

Current PS

3.51

Overvalued PS

14.31

Undervalued PS

-1.70

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best penny stock to buy

Intellectia · 45 candidates

Market Cap: 50.00M - 1.50BRegion: USPrice: $0.20 - $5.00List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $10.00 - $150.00Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Protalix Biotherapeutics Inc

238.45M

Kosmos Energy Ltd

633.78M

ProFrac Holding Corp

889.52M

Sypris Solutions Inc

75.77M

Context Therapeutics Inc

216.83M

Evolution Petroleum Corp

137.91M

best penny stocks to invest in

Intellectia · 17 candidates

Revenue Ttm: >= 10.00MRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 0.0%List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: >= $15.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Tigo Energy Inc

216.68M

TRX Gold Corp

448.36M

Satellogic Inc

585.75M

Bridger Aerospace Group Holdings Inc

158.30M

Coherus Oncology Inc

272.43M

Gold Resource Corp

216.89M

top performing penny stocks

Intellectia · 18 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $30.00Annual Revenue Yoy Growth: >= 10.0%

Ticker

Name

Market Cap$

Ur-Energy Inc

726.09M

Lightwave Logic Inc

634.08M

Satellogic Inc

486.33M

TROOPS Inc

474.59M

agilon health inc

395.14M

Century Therapeutics Inc

366.05M

Whales Holding RPID

Advent International, L.P.

Jaunty Global Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is Rapid Micro Biosystems Inc (RPID) stock price today?

The current price of RPID is 3.87 USD — it has increased 5.16 % in the last trading day.

What is Rapid Micro Biosystems Inc (RPID)'s business?

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.

What is the price predicton of RPID Stock?

Wall Street analysts forecast RPID stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPID is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Rapid Micro Biosystems Inc (RPID)'s revenue for the last quarter?

Rapid Micro Biosystems Inc revenue for the last quarter amounts to 7.84M USD, increased 3.08 % YoY.

What is Rapid Micro Biosystems Inc (RPID)'s earnings per share (EPS) for the last quarter?

Rapid Micro Biosystems Inc. EPS for the last quarter amounts to -0.26 USD, decreased -0.00 % YoY.

How many employees does Rapid Micro Biosystems Inc (RPID). have?

Rapid Micro Biosystems Inc (RPID) has 163 emplpoyees as of February 08 2026.

What is Rapid Micro Biosystems Inc (RPID) market cap?

Today RPID has the market capitalization of 171.53M USD.